Novartis AG (NVS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

97.875
+0.565+0.58%

Trading Jan 2 09:44 ET

195.68BMarket Cap11.49P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Zacks Dec 31 13:00 ET
Here's Why Novartis (NVS) Is a Strong Growth Stock
Zacks Dec 31, 2024 08:50 ET
Top Gap Ups and Downs on Monday: AR, DJT, MSTR and More
Moomoo NewsDec 30, 2024 18:00 ET · Markets
Novartis Reports Positive Results for Intrathecal Zolgensma
Seeking AlphaDec 30, 2024 10:58 ET
Novartis Says Gene Therapy for Spinal Muscular Atrophy Meets Primary Endpoint in Phase 3 Study
MT NewswiresDec 30, 2024 07:12 ET
Novartis AG (NVS.US): Its new experimental drug improves motor functions in children with SMA.
Novartis AG stated that their new experimental drug improved motor function in children with spinal muscular atrophy (SMA) in a late-stage study.
Zhitong FinanceDec 30, 2024 05:46 ET

Comments

10xStockPicks

Dec 29, 2024 17:56

Roaring Kitty New Years Eve Party, New Investment Idea For 2025

It is rumored Keith Gill will make new investments in 2025 potentially in the health care sector, based on the new Trump administration & RFK looking out for the health of Americans. Rumor is Keith is attending a New Years Eve party with a friend who's father take a statin alternative drug called NEXLIZET made by $Esperion Therapeutics (ESPR.US)$
This information comes from a friend of CNBC Jim Cramer who is also statin intolerant an...

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...